Public stock analysis · US45826J1051
Analyse Intellia Therapeutics stock
StocksterScore99
98.7
Current overview
Metrics for Intellia Therapeutics
Current course10,41 €
StocksterScore99/ 100
Analyst potential+95%
AI price target21,00 €
AI Analysis (Teaser)
AI analysis for Intellia Therapeutics
Adjusted price target instead of confirmation of 23.08 EUR
23.08 EUR is only around +7.5% above the derived fair value and therefore formally within the ±25% range, but appears slightly too ambitious for Intellia Therapeutics due to the very high clinical, regulatory and cash burn risks. A more plausible value is 21.50 EUR.
Quantitative plausibility check
The current price of 15.35 EUR implies an upside potential of around 40% up to 21.50 EUR, and up to 23.08 EUR it would be around 50%. This is fundamentally possible for a pre-profitable biotech, but must be covered by pipeline progress.
Historically, the s...
23.08 EUR is only around +7.5% above the derived fair value and therefore formally within the ±25% range, but appears slightly too ambitious for Intellia Therapeutics due to the very high clinical, regulatory and cash burn risks. A more plausible value is 21.50 EUR.
Quantitative plausibility check
The current price of 15.35 EUR implies an upside potential of around 40% up to 21.50 EUR, and up to 23.08 EUR it would be around 50%. This is fundamentally possible for a pre-profitable biotech, but must be covered by pipeline progress.
Historically, the s...
AI analysis updated on October 1, 2026